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ABSTRACT
Short-patch repair of DNA single-strand breaks and
gaps (SSB) is coordinated by XRCC1, a scaffold pro-
tein that recruits the DNA polymerase and DNA
ligase required for filling and sealing the damaged
strand. XRCC1 can also recruit end-processing
enzymes, such as PNK (polynucleotide kinase
3’-phosphatase), Aprataxin and APLF (aprataxin/
PNK-like factor), which ensure the availability of a
free 3’-hydroxyl on one side of the gap, and a
5’-phosphate group on the other, for the polymerase
and ligase reactions respectively. PNK binds to a
phosphorylated segment of XRCC1 (between its
two C-terminal BRCT domains) via its Forkhead-
associated (FHA) domain. We show here, contrary
to previous studies, that the FHA domain of PNK
binds specifically, and with high affinity to a multiply
phosphorylated motif in XRCC1 containing a pSer-
pThr dipeptide, and forms a 2:1 PNK:XRCC1
complex. The high-resolution crystal structure of a
PNK–FHA–XRCC1 phosphopeptide complex reveals
the basis for this unusual bis-phosphopeptide
recognition, which is probably a common feature
of the known XRCC1-associating end-processing
enzymes.
INTRODUCTION
Short-patch repair of DNA single-strand breaks and gaps
(SSBs) is coordinated by the multi-domain XRCC1 pro-
tein, which acts as a ‘scaﬀold’, recruiting and organising
the DNA polymerase (Polb) and DNA ligase (Lig3a) that
ﬁll in the missing nucleotides and seal the phosphodiester
backbone (1,2). Facile error-free repair of SSBs depends
on the availability of a free 30-hydroxyl on one side of the
gap, and a 50-phosphate group on the other, which respec-
tively permit template-directed DNA synthesis and
ATP-dependent ligation. However, in many circumstances
the DNA damage event that caused the gap, leaves
end-chemistries that cannot be extended or ligated, and
end-processing is required before SSB repair can be com-
pleted (3).
Polynucleotide kinase 30 phosphatase (PNK or PNKP)
is a bifunctional DNA end-processing enzyme that
facilitates SSB repair by phosphorylating 50-hydroxyls
and/or dephosphorylating 30-phosphates at the margins
of DNA single-strand gaps (4,5). PNK interacts, via its
N-terminal forkhead-associated domain (FHA), with a
segment of XRCC1 (between the central and C-terminal
BRCT domains) that is multiply phosphorylated by casein
kinase 2 (CK2) (6,7). PNK is also involved in non-
homologous end-joining repair of double strand breaks
(DSBs) via its interaction with a similar phosphorylated
segment C-terminal to the coiled-coil region of the struc-
turally unrelated XRCC4 scaﬀold protein (8,9). FHA
domains are implicated in protein–protein interactions in
a wide and diverse range of cellular proteins, and have
been found to bind preferentially to amino-acid sequences
containing a single phospho-threonine (pThr) residue.
Although previous studies had indicated that the PNK–
FHA domain has the conventional speciﬁcity for phospho-
threonine (9,10), the tight clustering of the identiﬁed
CK2 phosphorylation sites within XRCC1, suggests that
the situation might be more complicated. To gain some
insight into this we have analysed the binding of PNK
to phosphorylated XRCC1 protein biochemically, and
performed a quantitative calorimetric analysis of the inter-
action of the PNK–FHA domain with a series of phos-
phorylated XRCC1 peptides. We show here that, contrary
to previous studies, the FHA domain of PNK binds spe-
ciﬁcally, and with high aﬃnity to a bis-phosphorylated
*To whom correspondence should be addressed. Tel: 020 7153 5571; Fax: 020 7153 5457; Email: antony.oliver@icr.ac.uk
Correspondence may also be addressed to Laurence H. Pearl. Tel: 020 7153 5443; Fax: 020 7153 5457; Email: laurence.pearl@icr.ac.uk
 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.target sequence in XRCC1 containing vicinal pThr-pSer
residues. The structural basis for this is revealed by a
high-resolution crystal structure of the human PNK–
FHA domain binary complex with a phosphorylated
XRCC1-derived peptide. The distinctive characteristics
of the PNK–FHA are also found on the FHA domains
of two other DNA repair end-processing enzymes, APTX
(aprataxin) and APLF (aprataxin/PNK-like factor), deﬁn-
ing a distinct subset of FHA domains speciﬁcally adapted
to bis-phosphorylation-speciﬁc binding to the DNA repair
scaﬀold proteins, XRCC1 and XRCC4.
MATERIALS AND METHODS
Antibodies
The phospho-XRCC1 (pSer518/pSer519/pThr523) anti-
body used throughout this study was purchased from
Bethyl Laboratories, Montgomery, TX, USA (Catalogue
number: A300-059A).
Peptides
All peptides were synthesized and puriﬁed in-house by the
Peptide Synthesis Facility, ICR.
Expression vectors
pTWO-E is a modiﬁed pET-17b (Novagen, Merck
Chemicals, Nottingham, UK) vector engineered to
encode an N-terminal, 3C-Protease cleavable, His6
aﬃnity tag.
pTWO-B is a modiﬁed pFASTBAC1 (Invitrogen,
Paisley, UK) that encodes an N-terminal, 3C-Protease
cleavable, His6 aﬃnity tag.
pTHREE-E is a modiﬁed pGEX-6P-1 (GE Healthcare,
UK Ltd, Little Chalfont, UK) vector engineered to con-
tain the multiple cloning site of pET-17b and encodes an
N-terminal 3C-Protease cleavable, GST aﬃnity tag.
Gene synthesis
A synthetic gene encoding the N-terminal region of
human PNK (amino acids 1–139, including the
FHA domain) was constructed using recursive PCR
(11). Juniper—an in-house synthetic gene design pro-
gram—selected the sequences of the required overlapping
oligonucleotides. By choosing an average length of
70 bases, eight oligonucleotides were needed for gene con-
struction, the sequences of which are shown below:
‘Forward’ oligos—50–30:
1. CATATGGGTGAAGTTGAAGCTCCAGGTCGT
CTGTGGCTGGAATCCCCGCCGGGCGAAGC
TCCGCCGATC
2. GGGTCGTGGTCCGCTGACTCAGGTTACCGA
CCGTAAATGCTCCCGTACTCAGGTAGAACT
GGTTGCTGACCC
3. GCGTTAACCCGTCCACCACCGGCACCCAGG
AACTGAAACCGGGTCTGGAAGGTTCCCTG
GGTGTTGGTGACA
4. ACCCTGCGTTGGGAAGAAACCCGTACCCCG
GAATCCCAGCCGGACACCCCGCCAGGTACC
CCGCTGGTTTCC
‘Reverse’ oligos—50–30:
5. CAGCGGACCACGACCCAGAACCAGAGCCT
GACCGTCGGACGGCAGGAAGATCGGCGG
AGCTTCGC
6. GTGGACGGGTTAACGCCCAGCTGTTTAACA
GCAACGGTGCGGGTTTCCGGGTCAGCAA
CCAGTTCT
7. TTCTTCCCAACGCAGGGTCAGCGGGTGCAG
ACCGTTAACCAGGTACAGGGTGTCACCAAC
ACCCAGGG
8. GAATTCTCATCAACGTTTTTTCGGCAGTTCA
GCGTCACGTTTTTCGTCCTGGGAAACCAGC
GGGGTAC
The resulting product was blunt-end ligated into the
vector pCR-Blunt (Invitrogen Ltd, Paisley, UK). Several
clones were analysed and sequenced in-house, before sub-
cloning the DNA encoding amino acids 1–109 into the
expression vectors pTWO-E and pTHREE-E.
Protein expression and purification
PNK–FHA. The pTWO-E/PNK–FHA construct was
transformed into Escherichia coli strain Rosetta2(DE3)
pLysS (Merck Chemicals, Nottingham, UK). Cells
were cultured in shaker ﬂasks, containing LB media
[supplemented with 50mg/ml carbenicillin (Melford
Laboratories, Ipswich, UK) and 34mg/ml chlorampheni-
col (Sigma-Aldrich, Dorset, UK)], with growth conditions
of 378C and 220r.p.m. Cell density was monitored until an
OD of 0.5 was achieved when protein expression was
induced by the addition of IPTG to a ﬁnal concentration
of 1mM. Cells were harvested after 3h by centrifugation,
at 5000g for 10min at 48C, and the resulting pellet stored
at  808C until required.
The cell pellet resulting from 5l of expression culture
was resuspended, on ice, in 45ml of buﬀer A: 50mM
HEPES/HCl pH 7.5, 200mM NaCl, 10% v/v glycerol,
10mM imidazole, supplemented with protease inhibitors.
Cells were lysed by sonication, then clarifed by high-speed
centrifugation at 40000g, for 1h at 48C. The resulting
supernatant was ﬁltered through 4mm ﬁlter.
Ten millilitres of Talon (Takara Bio Europe) resin was
added to the ﬁltered supernatant and incubated, with
mixing, at 48C for 30min. The unbound fraction was
removed by passing the slurry through an empty
gravity-ﬂow chromatography column. The retained resin
was washed with 200ml of buﬀer A. The retained protein
was eluted by the addition of buﬀer B: 50mM HEPES/
HCl pH 7.5, 200mM NaCl, 10% v/v glycerol, 300mM
imidazole. Fractions containing the protein were identiﬁed
by SDS–PAGE, pooled, then concentrated to a volume of
10ml using Vivaspin 20 (5000 MWCO) concentrators
(Sartorius Stedim Biotech, Goettingen, Germany), before
being applied to a Superdex 75 gel ﬁltration column, pre-
equilibrated with buﬀer C: 20mM HEPES/HCl pH 7.5,
250mM NaCl, 1mM DTT, 1mM EDTA. Fractions con-
taining the protein were again identiﬁed by SDS–PAGE,
pooled, and then incubated with 3C-Protease (PreScission
protease, GE Healthcare) overnight, at 48C to remove the
aﬃnity-tag when required.
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Healthcare) then added to the sample and then incubated
with mixing, at 48C for 30min, to remove the 3C-Protease.
The resin was removed by passing the slurry through a
gravity-ﬂow chromatography column. The protein was
again concentrated, and as before, applied to a Superdex
75 gel ﬁltration column (GE Healthcare). Fractions con-
taining the puriﬁed protein were identiﬁed, and then con-
centrated to 15mg/ml, where it was either stored at 48C
for immediate use, or snap-frozen at  808C for long-term
storage.
XRCC1DN. A full-length clone of human XRCC1 was
obtained by PCR using Human MTC Panel I (Takara
Bio Europe, Saint-Germain-en-Laye, France) as a
template.
Sub-cloning of the DNA encoding amino acids 218–633
into the vectors pTWO-E and pTWO-B produced the
XRCC1"N constructs for expression in E. coli and Sf9
insect cells, respectively. Recombinant baculovirus expres-
sing XRCC"N was generated from the pTWO-B donor
vector, following the manufacturer’s recommended
protocol (Invitrogen).
Biochemical and biophysicalexperiments
Isothermal titration calorimetry. Heats of interaction were
measured on a VP-ITC microcalorimeter (MicroCal
Europe, Milton Keynes, UK) with a cell volume of
1.458ml. Puriﬁed PNK–FHA was dialysed overnight in
assay buﬀer (20mM HEPES/HCl pH 7.5, 250mM
NaCl, 1mM EDTA and 1mM TCEP).
For the PNK–FHA/XRCC1 phosphopeptide interac-
tions, 28 injections of 10ml of 400mM peptide were
injected into 40mM PNK–FHA at 108C.
The heat of dilution was determined in a separate exper-
iment by injecting peptide into the sample buﬀer. Data
corrected for the heat of dilution were ﬁtted using a
non-linear least square curve-ﬁtting algorithm (Microcal
Origin) with three ﬂoating variables: stoichiometry, bind-
ing constant and change in enthalpy of interaction. All
peptides were dissolved in assay buﬀer. Concentrations
were determined by UV spectroscopy using a ND-1000
spectrophotometer (NanoDrop Products, Wilmington,
DE, USA) and a molar extinction coeﬃcient of
1440M
 1cm
 1 at 274nm (due to the single tyrosine resi-
due present in each peptide sequence).
Crystallization, data collection and refinement
PNK–FHA. Crystallization trials of PNK–FHA were car-
ried out at 15mg/ml, in hanging drop experiments, at 208C
using MDL Structure Screen I. Crystals were obtained in
condition 32 (0.1M Tris–HCl pH 8.5, 2.0M ammonium
sulphate). No further optimization of the condition was
required, as crystals diﬀracted in-house to a resolution of
2.2A ˚ . The crystals were cryo-protected by swiping through
successive buﬀers that contained increasing amounts of
glycerol, to a ﬁnal concentration of 20% v/v.
Data to 1.4A ˚ were collected from a single crystal at
100K at the ESRF, Grenoble, France. Images were inte-
grated using MOSFLM (12), and reduced/scaled using
programs of the CCP4 suite (13). The protein crystallized
in the spacegroup P21 with cell dimensions of a=31.81A ˚ ,
b=40.05A ˚ , c=37.51A ˚ and  =90.96. A single molecule
comprised the asymmetric unit.
Initial phases were calculated by molecular replacement
[Phaser (14)] using the solution structure of the murine
PNK FHA domain (PDB: 1UJX) as a search model.
The calculated diﬀerence maps were then used to build a
molecular model, both automatically by ARP/wARP (15)
and manually using Coot (16). Iterative cycles of reﬁne-
ment [REFMAC5 (17)] and manual intervention pro-
duced the current model which consists of 775 protein
atoms, 144 solvent atoms and two sulphate ions with
R=0.150 and Rfree=0.183 for 5% of the data omitted
from reﬁnement. Coordinates have been deposited in the
Protein Databank (PDB: 2BRF).
Statistics for the data collection and reﬁnement are
given in Table S1 of the Supplementary Data.
PNK–FHA/XRCC1 phosphopeptide complex. The single-
point mutant L99E was generated by using a
QuickChange Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA, USA) following the manufacturer’s recom-
mended protocol. The mutant protein was expressed and
puriﬁed exactly as the wild-type protein.
Several of the XRCC1-derived phosphopeptides
described in this study were used in co-crystallization
trials, however reproducible hits were only obtained
with the triple-phosphorylated YAGpSpTDENpTDSE
peptide.
Protein and peptide were combined at a 2:1 ratio, then
incubated at 48C for 1h, prior to crystallization screening
in hanging drop experiments at 208C. Initial hits were
obtained in condition 44 of the PEGS II suite (Qiagen
Ltd, West Sussex, UK): 0.1M HEPES pH 7.5, 0.2M
CaCl2, 30% w/v PEG 4000.
This was optimized, again in hanging drops at 208C, to
mixing 1ml of the protein/peptide complex (15mg/ml,
with respect to protein, in 20mM HEPES/NaOH pH
7.5, 250mM NaCl, 1mM EDTA, 1mM TCEP) with 1ml
of precipitant containing 0.1M Tris–HCl pH 8.5, 0.25M
CaCl2, 28% w/v PEG 4000 and 0.2M NDSB-221.Crystals
were cryo-protected, for data collection, by a rapid swipe
through successive buﬀers containing increasing amounts
of glycerol, to a ﬁnal concentration of 20% v/v.
Diﬀraction data to 1.85A ˚ were collected from a single
crystal at 100K on station I04at the Diamond Light
Source, Didcot, UK. Data were processed and scaled
as before using the software packages MOSFLM and
Scala. The protein crystallized in the spacegroup P3
with cell dimensions of a=56.90A ˚ , b=56.90A ˚ ,
c=62.77A ˚ . Two molecules of PNK–FHA comprised
the asymmetric unit.
Phases were calculated by molecular replacement using
the crystal structure of PNK–FHA as a search model.
Diﬀerence electron density corresponding to the bound
peptide was readily observed in the initial maps. A molec-
ular model was built, both automatically by ARP/wARP
and manually using Coot. Iterative cycles of reﬁnement
(REFMAC5) and manual intervention produced the
current model which consists of 1508 protein atoms,
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Rfree=0.24 for 5% of the data omitted from reﬁnement.
Coordinates have been deposited in the Protein Databank
(PDB: 2W3O).
Statistics for the data collection and reﬁnement are
given in Table S1 of the Supplementary data.
RESULTS
Expression and purification of phosphorylatedXRCC1
We had previously characterized in our laboratory a con-
struct expressing a truncated form of human XRCC1 that
was resistant to proteolytic degradation—XRCC1N
(amino acids 218–633)—containing both BRCT domains
and the intervening linker region (Figure 1A). As for full-
length XRCC1 (6), the truncated protein encoded by this
construct was phosphorylated when puriﬁed from
insect cells (Figure 1B); conﬁrmed by western blot with
a polyclonal antibody that simultaneously detects
phosphorylation sites (pS518/pT519/pT523) within the
linker region connecting the two BRCT domains of
XRCC1 (a-pXRCC1). The reactivity to this antibody
was readily lost on incubation with  -phosphatase. In
contrast, XRCC1N expressed in and puriﬁed from
E. coli, showed no inherent reactivity to the antibody,
Figure 1. PNK–FHA protects CK2-phosphorylated XRCC1 from dephosphorylation. (a) Schematic representation of the domain structure of
human XRCC1. The predicted amino-acid boundaries for each domain are indicated, with a dotted box delineating the extent of the XRCC1N
expression construct used in this study. The positions of the known phosphorylation sites within the linker region connecting the two C-terminal
BRCT domains are also shown. (b) XRCC1N expressed in insect cells (Sf9) is phosphorylated, as detected by a phospho-speciﬁc polyclonal
antibody (Bethyl Laboratories, A300-059A). Incubation with  -phosphatase readily removes the detected sites of phosphorylation. In contrast,
XRCC1N expressed in E.coli is not phosphorylated. One hundred micrograms of puriﬁed XRCC1N protein was incubated with 50mgo f
 -phosphatase for a period of 1h at room temperature, before being analysed by SDS–PAGE. (c) Incubation of the E.coli expressed XRCC1N
with recombinant maize CKII reproduces the phosphorylation observed in Sf9 cells. Sixty micrograms of puriﬁed XRCC1N was incubated with
increasing amounts of CKII (ranging from 0 to 95mg), for a period of 2h at room temperature. (d) Cell lysates from insect cells expressing His6-
tagged XRCC1N and E.coli expressing GST-tagged PNK–FHA were mixed, then applied to two sequential aﬃnity columns (Talon/IMAC and
Glutathione Sepharose). The SDS–PAGE analyses of the eluates from each step are shown. (e) The presence of the PNK–FHA domain protects, at
least, the three phosphorylation sites detected by the polyclonal antibody in XRCC1 from the enzymatic action of  -phosphatase. SDS–PAGE gels
were stained with SimplyBlue SafeStain (Invitrogen, Paisley, UK).
1704 Nucleic Acids Research, 2009, Vol. 37,No. 5but developed a signal on incubation with maize CK2
(Figure 1C) conﬁrming previous observations that these
sites are targets for CK2 phosphorylation (6).
Affinity capture of XRCC1"Nby the FHA domain ofPNK
To test the functionality of the XRCC1N construct in
binding PNK, we expressed the FHA domain of human
PNK (PNK–FHA: amino acids 1–109) as a GST-fusion in
E. coli, and incubated cell lysates containing PNK–FHA
and XRCC1N (from insect cells) together. Both proteins
co-eluted in successive IMAC and Glutathione Sepharose
aﬃnity capture steps (Figure 1D), conﬁrming that the
PNK–XRCC1 interaction does not require the N-terminal
part of XRCC1. A puriﬁed PNK–FHA–XRCC1N com-
plex could then be obtained with further chromatographic
steps, following proteolytic removal of the GST and His6
aﬃnity tags.
PNK–FHA protects XRCC1 phosphorylation sites
The binding site for PNK has previously been localized to
the  150 amino-acid segment linking the two BRCT
domains in XRCC1, which contains the major documen-
ted CK2 phosphorylation sites pSer518, pThr519,
pThr523 and pSer525 (6,7), the ﬁrst three of which are
detected by the a-pXRCC1 phospho-speciﬁc antibody.
To conﬁrm that these sites are directly involved in the
interaction with PNK, we analysed the ability of the pur-
iﬁed PNK–FHA domain to protect the phosphorylation
sites in insect cell-puriﬁed XRCC1N from the enzymatic
action of  -phosphatase (Figure 1E). Isolated XRCC1N
was rapidly dephosphorylated as before, as judged by loss
of reactivity to the a-pXRCC1 antibody.
However, within the XRCC1N–PNK–FHA complex,
the sites detected by the antibody were protected from the
enzymatic activity of  -phosphatase, although the electro-
phoretic mobility of XRCC1N was slightly altered;
suggesting that some additional phosphorylation sites
were removed.
The experiment conﬁrms the interaction of PNK–FHA
with this particular region of XRCC1, and suggesting that
all three phosphorylation sites might be involved in the
PNK–FHA interaction.
Isothermal titration calorimetry of PNK–FHA interaction
withdefined XRCC1 phospho-peptides
As at least three of the documented CK2 sites (pSer518,
pThr519 and pThr523) appeared to be involved in PNK
recruitment, we sought to determine the contribution
to PNK–FHA-binding provided by each XRCC1 phos-
phorylation site, individually and in combination, using
isothermal titration calorimetry with synthetic phospho-
peptides (Table 1).
No binding of PNK–FHA was detected to a non-
phosphorylated XRCC1-derived peptide, or to peptides
mono-phosphorylated on either Ser518 or Ser525. PNK–
FHA did however bind weakly to a peptide phosphory-
lated on Thr523 with Kd= 13.5mM and an estimated
molar ratio (N=0.88) consistent with a single binding
site (Figure 2A). Slightly tighter binding was observed
with a pT519 peptide (Kd=10.6mM), but at a molar
ratio more consistent with two FHA molecules binding
to a single peptide (N=0.61). When Thr519 and Thr523
were phosphorylated in the same peptide, PNK–FHA
bound  16-fold tighter than to either of the mono-pT
peptides, with a Kd=0.7mM. Again, the estimated stoi-
chiometry of the interaction (N=0.51), suggesting that
two copies of PNK–FHA bound simultaneously to the
XRCC1 peptide.
While no binding was observed to a peptide only phos-
phorylated on Ser518, when this residue was phosphory-
lated in addition to Thr519 within the same peptide,
PNK–FHA bound >8-fold tighter (Kd=1.23mM) than
to the peptide only containing pThr519, again with 2:1
stoichiometry (N=0.51). Signiﬁcantly greater aﬃnity
(Kd=0.19mM), but again with 2:1 stoichiometry
(N=0.46), was observed with the tris-phosphorylated
pSer518/pThr519/pThr523 peptide (Figure 2B). However
adding the fourth putative CK2 phosphorylated residue,
pSer525, oﬀered no signiﬁcant further increase in aﬃnity.
The consistent observation of a 2:1 stoichiometry for
PNK–FHA-binding to all the peptides tested, other than
that phosphorylated on Thr523 only, was surprising. To
determine if this was related to the use of the isolated
FHA domain, we repeated the titrations with full-length
human PNK, against the pSer518/pThr519, and pSer518/
pThr519/pThr523/pSer525 peptides. The measured aﬃ-
nities for these peptides (Kd=1.57mM and 0.10mM,
respectively) were comparable to those obtained with the
isolated FHA domains, and the stoichiometries obtained
for the full-length proteins (N=0.61 and 0.49) were sim-
ilarly consistent with formation of 2:1 complexes with the
peptide in both cases (Figure 2C). Finally we inverted
the ITC experiment from the normal arrangement with
the protein in the cell and the peptide injected. When
PNK–FHA was injected into the cell containing
the pSer518/pThr519 peptide, the measured aﬃnity
(Kd=2.23mM) was comparable to that obtained in the
inverted experiment, with the measured stoichiometry
(N=1.76) inverted, but fully consistent with formation
of a 2:1 protein–peptide complex (Figure 2D).
The binding data are suggestive of two possible PNK–
FHA-binding sites within the 12 residues of the XRCC1
CK2 cluster—a primary site centred on pThr519 and a
secondary site centred on pThr523. The 1:1 stoichiometry
for binding to the pThr523-only peptide as compared to
the 2:1 stoichiometry for all the peptides containing
Table 1. ITC dissociation constants and stoichiometry
Peptide Sequence Kd (mM) N
YAGSTDENTDSE No binding –
YAGSTDENTDSE No binding –
YAGSTDENTDSE No binding –
YAGSTDENTDSE 10.58 0.28 0.61
YAGSTDENTDSE 13.49 1.296 0.88
YAGSTDENTDSE 0.76 0.22 0.51
YAGSTDENTDSE 1.23 0.04 0.51
YAGSTDENTDSE 0.19 0.02 0.46
YAGSTDENTDSE 0.14 0.01 0.50
YAGSTDENTDSE 24.18 1.44 0.56
YAGSTDENVDSE 1.7 0.06 0.91
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binding, whereby an FHA bound to Thr519 can facilitate
binding of a second FHA to Thr523 (most tightly when
phosphorylated), but not the other way round. To test
this, we made a further pSer518/pThr519 peptide in
which the kernal of the putative secondary site, Thr523,
was mutated to valine—a residue isosteric with threonine,
but unable to make the polar interactions that are likely to
Figure 2. Isothermal titration calorimetry of PNK binding to XRCC1 phospho-peptides. (a) ITC-binding curves for injection of XRCC1 peptides
phosphorylated on Thr523 (left), Thr519 (middle), and on both Thr519 and Thr523 (right), into a microcalorimeter cell containing PNK–FHA (see
Methods section). The mono-phosphorylated peptides show weak binding, while the doubly phosphorylated peptide binds with sub-micromolar
aﬃnity. Both peptides containing pThr518 show binding stoichiometry, (corresponding to the inﬂexion point of the curve) consistent with a 2:1
PNK–FHA:XRCC1 peptide complex. (b) As (a) but for peptide phosphorylated on pSer518 and pThr519 (left), and on pSer518, pThr519 and
pThr523 (right). Aﬃnities are >8-fold and >50-fold tighter, respectively, than the mono-phosphorylated pThr519 peptide. Binding stoichiometry in
both cases indicates a 2:1 PNK–FHA:XRCC1 peptide complex. (c) Binding curves for injection of a pSer518 and pThr519 peptide (left) or a pSer518,
pThr519, pThr523 and pSer525 peptide (right), into a cell containing full length human PNK. Aﬃnities compare with those for the isolated FHA
domain, and the binding stoichiometry remains consistent with a 2:1 PNK:XRCC1 peptide complex. (d) Inverted experiment, where PNK–FHA
protein is injected into a cell containing an XRCC1 pSer518, pThr519 peptide. In this orientation of the experiment the binding stoichiometry is
again consistent with formation of a 2:1 PNK:XRCC1 peptide complex, conﬁrming that the observation is not a result of the experimental set-up.
(e) Binding curves for injection of an XRRC1 peptide, phosphorylated on Ser518 and on Thr519, but with Thr523 mutated to valine. Removal of
the threonine residue ablates the second binding site, so that only a single FHA domain now binds.
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a comparable aﬃnity (Kd=1.70mM) to the equivalent
wild-type peptide (Kd=1.23mM), but with a stoichiome-
try (N=0.91) indicative of a single site of binding, con-
sistent with abrogation of the secondary binding site by
the Thr523Val mutation (Figure 2E).
Structural basis forbis-phospho-peptidebinding
by PNK–FHA
The strong additive interaction we observe for the PNK–
FHA binding to the bis-phosphorylated pS518/pT519
motif is clearly diﬀerent from the speciﬁcity previously
described for FHA domains in general, but most impor-
tantly also diﬀers from that ascribed to the PNK–FHA
domain itself in previous studies (9). To investigate this
further we sought to obtain co-crystals of human PNK–
FHA/bound to XRCC1 phospho-peptides whose binding
we had characterized. However initial attempts only
yielded crystals of the unliganded FHA domain (PDB:
2BRF), which had an unusually low solvent content
( 38% v/v) and diﬀracted strongly to high resolution.
Careful analysis of the crystal packing in this structure
revealed a crowded environment around the expected
peptide-binding site, incompatible with retention of the
peptide ligand on formation of this very stable lattice.
We therefore introduced a mutation into the protein
(Leu99Glu) in a residue involved in a substantial hydro-
phobic crystal packing interface, but distant from the
peptide-binding site, with the aim of preventing formation
of this crystal form. Using the mutant FHA domain we
obtained a new crystal form containing a complex of the
FHA domain and the tris-phosphorylated XRCC1
peptide (pSer518/pThr519/pThr523).
As in the previously described murine PNK–FHA–
XRCC4 peptide complex (10), the XRCC1-peptide
binds across the tips of the loops connecting the b-strands
that form either face of the FHA domain structure
(Figure 3A). Clear electron density is visible for the
bound peptide from XRCC1 residue Tyr515 to Asn522,
including the phosphorylated residues pSer518 and
pThr519. However the third phosphorylated residue
pThr523 and the three residues following that, are not
resolved despite our ‘crystal engineering’ attempts;
the packing of the FHA domains within the new crystal
lattice seemingly incompatible with a 2:1 protein; peptide-
binding mode.
The peptide makes extensive polar and hydrophobic
interactions with the FHA domain (Figure 3B). At the
N-terminus XRCC1-Tyr515 packs between the side
chains of PNK Pro37 and Thr42—the conformation of
Tyr515 suggests that the chain N-terminal to this would
not contact the FHA domain. C-terminal to this, the main
chain carbonyls of Tyr515 and the two consecutive resi-
dues Ala516 and Gly517, are all directed down towards
the FHA domain, and make hydrogen bonding interac-
tions with the guanidinium head group of Arg35. This
residue also hydrogen-bonds to the Og of the phos-
phorylated pThr519. The interaction with Arg35 ﬁxes
the conformation of the XRCC1 peptide from residue
515 to residue 519, and locks it between the side chains
of Arg44 and Arg48, which form a narrow hydrophobic
but intensely charged clamp, around the main chain
at Gly517 and the phosphorylated serine, pSer518
(Figure 3C). The Ne and NH moieties of Arg48 also pro-
vide additional hydrogen bonds to the phosphate group
of pThr519.
The pendant phosphate group of pSer518 has two alter-
nate conformations in the crystals, related by a  1208
rotation around the Ca-Cb bond. In either conformation,
the phosphate group is in close proximity to the guanidi-
nium head-groups of one or other of the side chains of
Arg44 or Arg48, making direct or water bridged hydro-
gen-bonding interactions. In any case, the proximity of the
negatively charged phosphate group to both these posi-
tively charge side-chains would provide a very favourable
electrostatic interaction.
Whether both these favourable alternative conforma-
tions would persist in free solution is unclear, as the tip
of the phosphate group is involved in interactions with a
calcium ion required for crystal formation, and this likely
perturbs the conformational energetics of the pSer518
side-chain conformation. In contrast, the pendant phos-
phate of pThr519 is locked down in a cage of hydrogen
bonds provided by the side chain hydroxyl of PNK Ser47,
and peptide and side-chain nitrogens of PNK Arg48
(Figure 3D).
Beyond pThr519, the conformation of the XRCC1 pep-
tide is determined by main-chain to side-chain hydrogen
bonding interactions with the side chain of PNK Asn70
and Lys45. The visible C-terminus of the XRCC1 peptide
is locked down by a bidentate amide–amide interaction
between the side chains of XRCC1 Asn522 and PNK
Asn97.
DISCUSSION
The FHA domain is a widely utilized module for recog-
nition of phosphorylated motifs, in a range of cellular
systems (18,19). Recognition centres on the core pThr
residue, which interacts with a Ser-Arg sequence (47 Ser-
Arg 48 in hPNK) that is very highly conserved amongst
FHA domains. However, the determinants of speciﬁcity
outside of the core pThr vary considerably, with residues
preceding and/or following the pThr making substantially
diﬀerent contributions in the diﬀerent classes of FHA
domain (20). Previous studies of the PNK–FHA domain
and its interaction with XRCC4 (9,10) have highlighted
the importance of residues  2,  3 and +1 relative to the
pThr, and in particular the apparent absence of signiﬁcant
+3 interactions, unlike many other FHA domains, where
this is an important feature.
Specificity of PNK–FHA
In the XRCC1 peptide complex described here however,
PNK–FHA shows a clear and highly speciﬁc +3 interac-
tion involving the side chains of XRCC1 Asn522 and
PNK Asn97, indicating that, at least in this respect,
PNK–FHA may not be as distinctive as originally sug-
gested. The equivalent to XRCC1 Asn522 in XRCC4 is
a glutamic acid (Glu236), which is disordered in the
Nucleic Acids Research,2009, Vol.37, No. 5 1707XRCC4 peptide complex. Interestingly, Asn (as in
XRCC1) is indicated as the preferred +3 substituent in
a peptide array analysis of PNK–FHA-binding prefer-
ences (9) (Figure 4C therein), whereas Glu (as in
XRCC4) appears somewhat disfavoured.
The unusual sensitivity to the nature of the  2 and  3
substituents observed in the peptide array analysis (9),
is diﬃcult to reconcile with the crystal structure of
the PNK–FHA–XRCC1 peptide complex described
here, and indeed with the previously described PNK–
FHA–XRCC4 peptide complex (10). In both crystal struc-
tures the  2 and  3 residues of the peptide (XRCC1: G,A
– XRCC4: E,D) are actually distinguished by having no
side chain interactions with the FHA domain that could
Figure 3. Structure of PNK–FHA–XRCC1 phosphopeptide complex. (a) Overview of the binding of the XRCC1 peptide (stick model) to
residues forming the inter-strand loops in the PNK–FHA domain (cartoon rainbow coloured N-terminal:blue ! C-terminal:red). This and
all other molecular graphics were made with MacPyMol (DeLano Scientiﬁc). (b) Interactions of the N-terminal end of the XRCC1 peptide with
PNK–FHA (see text for details). The phosphate group on pSer518 shows dual conformations in the crystal structure, (shown as thick and thin
sticks), due to interactions with a calcium ion involved in formation of the crystal lattice. Ordered water molecules are shown as yellow spheres,
Ca2
+ ions as larger grey spheres. (c) The central part of the XRCC1 peptide consisting of the negatively charged residues pSer518, pThr519 and
Asp520 binds in a very basic recess on the FHA domain surface, generated by the side chains of arginine residues 35, 44 and 48, and Lys 45. The
molecular surface of PNK–FHA is shown coloured by electrostatic potential – positive:blue ! negative:red. (d) Interactions of the C-terminal end of
the XRCC1 peptide (see text for details). The C-terminal Asn522 of the XRCC1 peptide is anchored by a bidentate amide-amide interaction
with PNK residue Asn97.
1708 Nucleic Acids Research, 2009, Vol. 37,No. 5mediate speciﬁcity. Furthermore, the consensus derived
from the peptide array data, would apparently preclude
the  2 and  3 residues, Gly and Ala, that actually occur
in XRCC1, so its biological relevance is open to question
(Figure 4A and B).
PNK–FHA binds bis-phosphorylated motifs
Where PNK–FHA does genuinely appear distinctive, is in
its preferential binding to a bis-phosphorylated motif.
Thus while PNK–FHA binds the pThr519-XRCC1 pep-
tide with an aﬃnity  10mM, its aﬃnity for the pSer518/
pThr519 peptide is nearly 10 times greater. The contribu-
tion of the phosphorylated  1 residue is purely additive to
a necessary core pThr-dependent interaction, so that a
pSer518 monophosphorylated peptide shows no signiﬁ-
cant binding. The pSer in the  1 position relative to the
core pThr, is able to make direct hydrogen bonding inter-
actions with residues in the FHA domain, but will also
provide a strong favourable electrostatic interaction with
the intense positive charge generated by the side chains of
Arg 35, Arg 44 and Arg 48. Indeed, this, rather than any
speciﬁc recognition process, may be the explanation for
the apparent preference for acidic residues at the  2 and
 3 positions in the XRCC4 peptide array study (9).
Mass spectrometry analysis of tryptic digests of XRCC1
extracted from HeLa cells (6) indicated that an isolated
fragment (corresponding to amino acids 503–546) was
a mixture of tri- and tetra-phosphorylated species.
Additionally, it was noted that residues Ser518 and
Thr523 are consensus CK2 phosphorylation sites, whilst
those of Thr519 and Ser525 were considered to be atypical
or hierarchical sites. Together, these data strongly suggest
that pThr519 most likely only exists in cells in a bis-phos-
phorylated context (i.e. along with pSer518).
Previous studies of the interaction of PNK–FHA
with XRCC4 did not discover the preferential binding
to the adjacent bis-phosphorylated motif we describe
here for XRCC1. However, both XRCC1 and XRCC4
scaﬀold proteins share the core Ser-Thr-Asp-Glu motif,
Figure 4. Comparison of PNK–FHA interactions with XRCC1 and XRCC4. PNK–FHA interacts in a similar way with the XRCC1 phosphopeptide
(a), as with the XRCC4 peptide (b) apart from the additional interactions with pSer518 and Asn522 in the XRCC1 complex. That Ser518 was not
phosphorylated in the XRCC4 complex is probably responsible for the diﬀerent conformation observed for Arg44 in the two complexes. In both
cases, the residues at  2 and  3 relative to the pThr, make no side-chain contacts with the protein that could mediate selectivity for these positions,
and the speciﬁcity of FHA for the XRCC1 and XRCC4 sequences resides in the polar and electrostatic interactions with phosphorylated and acidic
residues at 0,  1, +1 and +2, the hydrophobic interaction with Tyr at  4, and (for XRCC1) with the amide-side chain of the Asn at +3. In the
schematics on the right, residues with a red (strictly) or orange (highly) background are conserved across FHA domains. Those with a green
background are involved in hydrophobic contacts with the bound XRCC1/XRCC4 peptide, whilst those with a grey background are involved in
making speciﬁc hydrogen bonds (as indicated by a line).
Nucleic Acids Research,2009, Vol.37, No. 5 1709in which the downstream acidic side chains directs
CK2-phosphorylation of the serine and threonine resi-
dues. Thus, it is highly likely that this motif is bis-phos-
phorylated in both cases, and bound by PNK–FHA in the
same way.
PNK is one of three mammalian DNA repair enzymes
with distinctive and related N-terminal FHA domains that
have so far been shown to bind to XRCC1 (6,21,22).
Although only the structure of the PNK–FHA is currently
available, the FHA sequences of PNK, APTX and APLF
show strong conservation of the distinct sequence motifs
that in PNK mediate interaction with the main speciﬁcity
determinants in XRCC1. While yet to be formally demon-
strated, the likelihood is therefore, that the FHA domains
of APTX and APLF will also show preferential binding to
the adjacent bis-phosphorylated pSer518-pThr519 motif.
Indeed, Aprataxin has been shown to bind with a higher
aﬃnity to a tris-phosphorylated XRCC1 peptide
(pSer518/pThr519/pThr523) than a mono-phosphorylated
peptide (pT523) (22).
While this work was in progress, the FHA domain of
the yeast checkpoint kinase Dun1p, was shown to bind
preferentially to a di-phospho-threonine motif generated
by ATM/ATR in the SQ/TQ cluster domain of the
upstream kinase Rad53 (23). However, unlike the adjacent
phosphorylated residues in the XRCC1 and XRCC4
motifs, the two pThr residues in Rad53 are separated by
two residues. Furthermore, the mode of interaction, as
indicated by an NMR structure of the Dun1-FHA
bound to a bis-phosphorylated Rad53 decapeptide, is
markedly diﬀerent, with no equivalent to the Ser-Arg
‘cage’ interaction seen in PNK and other FHA domains
(20), and with the N-terminal of the two pThr binding in a
similar region on the FHA domain as the tyrosine in the
XRCC1/XRCC4 motifs (Figure 5A and B).
Tandem binding sites inXRCC1
The sequence C-terminal to the common bis-phosphory-
lated binding motif is quite diﬀerent between the two DNA
repair scaﬀold proteins with which PNK interacts. XRCC1
possesses an additional threonine residue, again in the con-
text of downstream acidic residues (523 Thr-Asp-Ser-Glu-
Glu 527) that can also be phosphorylated by CK2 (6).
Using an aﬃnity puriﬁed polyclonal antibody speciﬁc to
a tris-phosphorylated XRCC1 peptide (see Methods sec-
tion) we found that Thr523, like the upstream pSer518 and
pThr519 appears protected from dephosphorylation by
PNK–FHA, and that PNK–FHA bound to a pThr523
mono-phosphorylated peptide with similar aﬃnity as to a
mono-phosphorylated pThr519 peptide. Taken together,
these data indicate that both the threonine residues in
this region of XRCC1 are capable of being phosphorylated
by CK2, and when phosphorylated, of providing binding
sites for PNK. Signiﬁcantly, the ITC data shows that the
two sites co-operate, and an XRCC1 peptide phosphory-
lated on both threonines binds two PNK–FHA molecules,
with >15-fold higher aﬃnity than for either site in isola-
tion, and with >50-fold higher aﬃnity when Ser518 is also
phosphorylated (Figure 6).
The co-operation between the two sites is however hier-
archical, with binding to the pThr519 (more so with simul-
taneous pSer518) being able to facilitate binding to the
Thr523 site, most tightly when phosphophorylated, but
to some degree even when not. That the second binding
site is indeed focussed on Thr523 is demonstrated une-
quivocally by the eﬀect of the Thr523Val mutation,
which shifts the binding stoichiometry to  1:1. The
nature of the interactions between the FHA domains,
that mediate co-operative binding to the pThr-sites
remain to be determined.
Figure 5. Diﬀerent modes of bis-phosphopeptide-binding in PNK and Dun1. The binding mode to PNK–FHA of the XRCC1 bis-phosphopeptide (a)
with adjacent pSer-pThr residues is markedly diﬀerent to that recently observed for a yeast Rad53 phosphopeptide containing two non-adjacent pThr
residues, to the FHA of the DNA damage checkpoint kinase Dun1 (PDB code 2JQL) (b). While the C-terminal phosphorylated residue is in a similar
topological position on the FHA domain, the N-terminal pThr in Dun1 binds in the  4 subsite, which is occupied by a tyrosine in PNK–FHA
complexes with XRCC1 and XRCC4 peptides.
1710 Nucleic Acids Research, 2009, Vol. 37,No. 5CONCLUSION
Recognition of a bis-phosphorylated motif provides PNK,
and probably the other FHA-domain DNA end-proces-
sing enzymes, APTX and APLF, with a unique mecha-
nism for highly speciﬁc recognition of their binding sites
in the XRCC1 and XRCC4 DNA repair scaﬀolds.
XRCC4 is known to be dimeric (24) and might in principle
therefore recruit two copies of PNK, APTX or APLF,
potentially in homo- and hetero-combinations, although
this is yet to be tested. XRCC1, although showing a degree
of dimerization at higher concentrations in vitro, is pri-
marily monomeric and interacts with nicked and gapped
DNA substrates as a monomer (25). We show here that
XRCC1 is also able to recruit two copies of PNK, and
possibly two copies of APLF or APTX. However our pre-
liminary data (not shown) suggests that it is not possible
to obtain a PNK–XRCC1–APTX hetero-complex, and
this is certainly consistent with the observation that
these enzymes reside in distinct XRCC1 complexes
in vivo (22). As PNK is a dual function enzyme, removing
30-phosphates from one end of a ssDNA gap and adding
50-phosphates at the other end, the presence of two bind-
ing sites on the XRCC1 scaﬀold may facilitate speciﬁc
access of one or other of the two PNK active sites to
their particular substrate ‘end’ of the gap (Figure 6B).
Further work will be required to test this hypothesis.
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